Aerovate Therapeutics Announces 24-Week Topline Results From Phase 2b Portion Of IMPAHCT Evaluating AV-101 For Pulmonary Arterial Hypertension
Portfolio Pulse from Benzinga Newsdesk
Aerovate Therapeutics announced positive 24-week topline results from the Phase 2b portion of the IMPAHCT trial evaluating AV-101 for pulmonary arterial hypertension.
June 17, 2024 | 12:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aerovate Therapeutics announced positive 24-week topline results from the Phase 2b portion of the IMPAHCT trial evaluating AV-101 for pulmonary arterial hypertension.
Positive trial results are likely to boost investor confidence in AVTE's pipeline, potentially driving the stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100